These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27295873)

  • 1. [Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
    Veszelyné Kotán E; Mészaros Á
    Acta Pharm Hung; 2016; 86(1):13-22. PubMed ID: 27295873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bisphosphonate use and related pharmaceutical issues II].
    Veszelyné Kotan E; Mészáros Á
    Acta Pharm Hung; 2016; 86(1):23-34. PubMed ID: 27295874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bisphosphonates for osseus invasion caused by bronchial carcinoma].
    Bartl R
    Dtsch Med Wochenschr; 2008 Nov; 133(48):2530. PubMed ID: 19021088
    [No Abstract]   [Full Text] [Related]  

  • 4. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
    Aspray TJ; Francis RM
    Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inflammation of the jaws during treatment with bisphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
    [No Abstract]   [Full Text] [Related]  

  • 8. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
    Lai PS; Chua SS; Chan SP
    J Clin Pharm Ther; 2012 Oct; 37(5):536-43. PubMed ID: 22380577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
    Lim JS; Jin SH; Kim SB; Lee JI
    J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of bisphosphonates in women: when to use and when to stop.
    Gatti D; Adami S; Viapiana O; Rossini M
    Expert Opin Pharmacother; 2015; 16(16):2409-21. PubMed ID: 26357942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the optimal duration of bisphosphonate therapy?
    Ott SM
    Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
    Cesareo R; Iozzino M; Alva D; Napolitano C; De Rosa B; Contini S; Mallardo L; Lauria A; Reda G; Orsini A
    Minerva Endocrinol; 2007 Dec; 32(4):275-95. PubMed ID: 18091664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral bisphosphonates: A review of clinical use in patients with bone metastases.
    Major PP; Lipton A; Berenson J; Hortobagyi G
    Cancer; 2000 Jan; 88(1):6-14. PubMed ID: 10618600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
    Verron E; Bouler JM
    Drug Discov Today; 2014 Mar; 19(3):312-9. PubMed ID: 23974069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.